Titre :

Infliximab exposure associates with radiologic evidence of healing in patients with crohn''s disease

Auteur(s) :

Bossuyt, Peter [Auteur]
Imelda General Hospital
Dreesen, Erwin [Auteur]
Catholic University of Leuven = Katholieke Universiteit Leuven [KU Leuven]
Rimola, Jordi [Auteur]
Clinic Barcelona Hospital Universitari
Devuysere, Sofie [Auteur]
Imelda General Hospital
De Bruecker, Yves [Auteur]
Imelda General Hospital
Vanslembrouck, Ragna [Auteur]
Catholic University of Leuven = Katholieke Universiteit Leuven [KU Leuven]
Laurent, Valerie [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Zappa, Magaly [Auteur]
Hôpital Beaujon [AP-HP]
Savoye-Collet, Celine [Auteur]
Service de Radiologie [CHU Rouen]
Pariente, Benjamin [Auteur]
Hôpital Claude Huriez [Lille]
Filippi, Jerome [Auteur]
Hôpital l'Archet
Baert, Filip J. [Auteur]
Dhaens, Geert R. [Auteur]
Academic Medical Center - Academisch Medisch Centrum [Amsterdam] [AMC]
Laharie, David [Auteur]
Hôpital Haut-Lévêque [CHU Bordeaux]
Peyrin-Biroulet, Laurent [Auteur]
Nutrition-Génétique et Exposition aux Risques Environnementaux [NGERE]
Vermeire, Severine [Auteur]
Catholic University of Leuven = Katholieke Universiteit Leuven [KU Leuven]

Titre de la revue :

Clinical gastroenterology and hepatology . the official clinical practice journal of the American Gastroenterological Association

Nom court de la revue :

Clin. Gastroenterol. Hepatol.

Date de publication :

2020-04-28

ISSN :

1542-7714

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Background & Aims Higher infliximab trough levels are associated with clinical and endoscopic remission in patients with Crohn's disease (CD). We investigated pharmacodynamic features of infliximab and radiological ...
Lire la suite >Background & Aims Higher infliximab trough levels are associated with clinical and endoscopic remission in patients with Crohn's disease (CD). We investigated pharmacodynamic features of infliximab and radiological healing. Methods We performed a substudy of the TAILORIX trial (patients with active luminal CD in Europe, treated with infliximab), analyzing baseline and week 54 magnetic resonance enterography (MRE) data. MREs were scored using the MaRIA score by blinded central readers. Radiologic response and remission were defined, based on MaRIA criteria in all segments, as scores below 11 and 7, respectively. We collected data on infliximab trough levels, biomarkers, and endoscopic findings. Our primary aim was to evaluate pharmacodynamic features associated with radiologic response and remission, based on MRE assessments at baseline and at 54 weeks after initiation of infliximab therapy. Results We analyzed data from 36 patients (50% female; median age 35.7 years; interquartile age range, 25.6–48.6 years; median disease duration, 1.5 months; interquartile duration range, 0.6–22.4 months). At week 54 of treatment, 36.4% of patients had a radiologic response, 30.3% of patients were in remission, and 71% had endoscopic features of remission. At baseline, there was a correlation between the CD endoscopic index of severity and MaRIA scores (κ = 0.46; P = .008), but we found no correlation at week 54 (κ = 0.06; P = .75). Radiologic remission correlated with infliximab trough level at week 14 (P = .049) when the infliximab trough level cut-off value was set at 7.8 μg/mL (area under the curve, 0.74; 75% sensitivity; 86% specificity; 90% negative predictive value; 57% positive predictive value). Radiologic response correlated with infliximab trough levels at week 14 (P = .048) when the infliximab trough level cut-off value was set at 7.8 μg/mL (area under the curve, 0.73; 70% sensitivity; 90% specificity; 86% negative predictive value; 78% positive predictive value) and with continuous pharmacologic evidence of response (infliximab trough levels above 5.0 μg/mL at all time points) (P = .034). Conclusions In a substudy of data from the TAILORIX trial of patients with active luminal CD, we identified a relationship between exposure to infliximab and radiologic evidence of outcomes.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2021-07-06T12:45:12Z
2024-02-06T12:18:50Z